Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × IT-101 × Clear all
NCT02010567 2020-11-03

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Terminated
32 enrolled 18 charts
Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT02389985 2020-05-28

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Lumos Pharma

Phase 1/2 Terminated
30 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡